WO2006104292A1 - Composition pharmaceutique qui comprend de l’acide arsénique, du meta-arsénite et des sels pharmaceutiquement acceptables - Google Patents
Composition pharmaceutique qui comprend de l’acide arsénique, du meta-arsénite et des sels pharmaceutiquement acceptables Download PDFInfo
- Publication number
- WO2006104292A1 WO2006104292A1 PCT/KR2005/000938 KR2005000938W WO2006104292A1 WO 2006104292 A1 WO2006104292 A1 WO 2006104292A1 KR 2005000938 W KR2005000938 W KR 2005000938W WO 2006104292 A1 WO2006104292 A1 WO 2006104292A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arsenite
- pharmaceutically acceptable
- acceptable salts
- meta
- sodium
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- DJHGAFSJWGLOIV-UHFFFAOYSA-N Arsenic acid Chemical compound O[As](O)(O)=O DJHGAFSJWGLOIV-UHFFFAOYSA-N 0.000 title abstract description 5
- 229940000488 arsenic acid Drugs 0.000 title abstract description 5
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 claims abstract description 26
- 208000030507 AIDS Diseases 0.000 claims abstract description 18
- JCKSISPHZHGQDO-UHFFFAOYSA-N [Na].[As](O)(O)(O)=O Chemical compound [Na].[As](O)(O)(O)=O JCKSISPHZHGQDO-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 abstract description 13
- 208000031886 HIV Infections Diseases 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 6
- 239000002207 metabolite Substances 0.000 abstract description 4
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- MHUWZNTUIIFHAS-XPWSMXQVSA-N 9-octadecenoic acid 1-[(phosphonoxy)methyl]-1,2-ethanediyl ester Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C\CCCCCCCC MHUWZNTUIIFHAS-XPWSMXQVSA-N 0.000 description 9
- 229940047047 sodium arsenate Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000036436 anti-hiv Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 231100000456 subacute toxicity Toxicity 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
Definitions
- This invention relates to a pharmaceutical composition for prevention and treatment of acquired immune deficiency syndrome comprising arsenic acid sodium, sodium meta-arsenite and their pharmaceutically acceptable salts. More specifically, this invention identifies that arsenic acid sodium, sodium meta-arsenite and their pharmaceutically acceptable salts, which are in vivo metabolites of AS2O3, have anti- HIV-I and anti-HIV-2 activities and thereby provides a pharmaceutical composition for prevention and treatment of acquired immune deficiency syndrome.
- the object of this invention is to provide a pharmaceutical composition for prevention and treatment of acquired immune deficiency syndrome.
- This invention relates to a pharmaceutical composition for prevention and treatment of acquired immune deficiency syndrome comprising at least one selected from the group consisting of arsenic acid sodium, sodium meta-arsenite and their pharmaceutically acceptable salts as active ingredients. This invention is more specifically described hereunder.
- the inventors of this invention have succeeded in identifying the anti-HIV-1 and anti-HIV-2 activities of arsenic acid sodium, sodium meta-arsenite and their pharmaceutically acceptable salts, which are in vivo metabolites of As 2 O 3 , and therefore this invention relates to a pharmaceutical composition for prevention and treatment of acquired immune deficiency syndrome comprising arsenic acid sodium, sodium meta-arsenite and their pharmaceutically acceptable salts.
- Arsenic acid sodium as one of the active ingredients of the pharmaceutical composition of the present invention, is an in vivo metabolite of AS2O3 and can be obtained from blood or living body or synthesized. It has been also known to be effective in curing leukemia or solid cancer.
- Sodium meta-arsenite as another active ingredient of the pharmaceutical composition of the present invention, is also an in vivo metabolite of AS2O3 and can be obtained from blood or living body or synthesized. It has been also known to be effective in curing leukemia or solid cancer.
- the above-mentioned arsenic acid sodium and sodium meta- arsenite can form pharmaceutically acceptable salts by reacting with inorganic acids such as HCl, acetic acid, bromic acid, and the like while they can also form pharmaceutically acceptable salts by reacting with alkali metal ions such as sodium, potassium, and the like. Therefore, the present invention also includes pharmaceutically acceptable salts of both arsenic acid sodium and sodium meta- arsenite.
- arsenic acid sodium and sodium meta-arsenite and their pharmaceutically acceptable salts have anti-HIV-1 and anti-HIV-2 activities, it is apparent that their mixture would also have anti-HIV-1 and anti-HIV-2 activities. Therefore, arsenic acid sodium and sodium meta-arsenite and their pharmaceutically acceptable salts can be used as active ingredients of a pharmaceutical composition for prevention and treatment of AIDS. Further, in manufacturing pharmaceutical drugs containing the above-mentioned active ingredients, they can be prepared in the form of tablets, powder, granules, capsules, suspensions, emulsions, or unit preparations for parenteral administration or other preparations for multiple administrations by containing a pharmaceutically acceptable carriers or excipients.
- the effective amount of active ingredients for the above-mentioned pharmaceutical composition may vary greatly depending on the age, physical condition, body weight of a patient.
- the effective amount is 0.1 - 30 mg/kg/day, more preferably 0.5 - 3 mg/kg/day.
- administration can be done once or a few times daily within the effective range.
- Human T cell transgenic cell line MT-4 was used after culturing in RPMI1640, a medium containing 10% bovine fetal serum. Besides, HIV-I and HIV-2 lines were kindly provided by National Institute for Biological Standards and Control (NIBSC) in United Kingdom. Each virus was allowed to respectively infect H9 cell and subcultured at intervals of about 3 to 4 days. The culture was centrifuged and the resulting supernatant was collected as solution of viral seed solution and stored at - 70 0 C, which was used after thawing at 37 0 C immediately prior to use.
- RPMI1640 a medium containing 10% bovine fetal serum.
- HIV-I and HIV-2 lines were kindly provided by National Institute for Biological Standards and Control (NIBSC) in United Kingdom. Each virus was allowed to respectively infect H9 cell and subcultured at intervals of about 3 to 4 days. The culture was centrifuged and the resulting supernatant was collected as solution of viral seed solution and stored at - 70 0 C,
- CCID50 50% tissue culture infectious dose
- Example 1 Effect of in vitro anti-HIV Activity In vitro experiments were conducted to investigate the anti-HIV effects of sodium arsenate and sodium meta-arsenite.
- sodium arsenic acid and sodium meta-arsenite of the present invention were shown to have superior anti-HIV activities to that of AZT, a currently available AIDS treating agent while having less cytotoxici y at the same concentration.
- Example 2 Test of Subacute Toxicity on Mice Subacute toxicity for oral administration were conducted using 5 week old specific pathogen free (SPF) CD-I mice. Sodium arsenate and sodium meta-arsenite of the present invention were respectively dissolved in 10% glucose solution and orally administered once daily with a concentration of 10, 20, 40 and 80 mg/kg/day, respectively, to 10 mice in each group for 14 days. Then, after 14 days of restoration period, biochemical and hematological tests were conducted on the 29 th day and organ abnormalities were observed by naked eyes after autopsies. Besides, clinical syndromes, change in body weight, and mortality of mice after the administration were observed daily.
- SPPF pathogen free
- mice there were no dead mice or mice with apparent clinical syndromes observed in a group where the above-mentioned two test materials were administered with the concentration of 10, 20 and 40 mg/kg and also no toxicological change was observed in body weight, hematological test, hematobiochemical test, and autopsies. On the contrary, in a group where sodium arsenate was administered with a concentration of 80 mg/kg, one mouse was dead on the 13 th day after the oral administration and two mice showed respiratory problems but no additional death was observed.
- One tablet (200 mg) was mixed with 100 mg of active ingredients (arsenic acid sodium, meta-arsenite or their pharmaceutically acceptable salts), 40 mg of lactose, 51 mg of corn starch and 2 mg of colloidal silicon dioxide.
- active ingredients arsenic acid sodium, meta-arsenite or their pharmaceutically acceptable salts
- lactose lactose
- 51 mg of corn starch 50 mg
- colloidal silicon dioxide colloidal silicon dioxide.
- the mixture was pulverized after adding 3% polyvinylpyrolidone solution and then passed through a size 14 mesh. After drying, the resultant was passed again through the size 14 mesh and added with 1 mg of magnesium stearate to obtain the mixture in the form of a tablet.
- the pharmaceutical composition of the present invention comprising arsenic acid sodium,sodium meta-arsenite or their pharmaceutically acceptable salts as active ingredient have excellent anti-HIV-1 and anti-HIV-2 activities and are thus expected to be very useful for the prevention and treatment of acquired immune deficiency syndrome.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne une composition pharmaceutique pour la prévention et le traitement du syndrome d’immunodéficience acquise comprenant de l’acide arsénique, du meta-arsénite et leurs sels pharmaceutiquement acceptables. Plus spécifiquement, cette invention détermine que l’acide arsénique sodique, le méta-arsénite sodique et leur sels pharmaceutiquement acceptables, qui sont des métabolites du As203 in vivo, ont des activités anti-VIH 1 et anti-VIH 2 et fournissent ainsi une composition pharmaceutique pour la prévention et le traitement du syndrome d’immunodéficience acquise.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2005/000938 WO2006104292A1 (fr) | 2005-03-31 | 2005-03-31 | Composition pharmaceutique qui comprend de l’acide arsénique, du meta-arsénite et des sels pharmaceutiquement acceptables |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2005/000938 WO2006104292A1 (fr) | 2005-03-31 | 2005-03-31 | Composition pharmaceutique qui comprend de l’acide arsénique, du meta-arsénite et des sels pharmaceutiquement acceptables |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006104292A1 true WO2006104292A1 (fr) | 2006-10-05 |
Family
ID=37053533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2005/000938 WO2006104292A1 (fr) | 2005-03-31 | 2005-03-31 | Composition pharmaceutique qui comprend de l’acide arsénique, du meta-arsénite et des sels pharmaceutiquement acceptables |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006104292A1 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009072779A1 (fr) * | 2007-12-04 | 2009-06-11 | Sang Bong Lee | Composition contenant du méta-arsénite de sodium pour le traitement de l'hépatite c |
| WO2011031890A3 (fr) * | 2009-09-10 | 2011-08-25 | Kominox, Inc. | Thérapie ciblée sur des cellules souches cancéreuses et contre un cancer pharmacorésistant |
| WO2011034775A3 (fr) * | 2009-09-18 | 2011-10-06 | Kominox, Inc. | Méthodes de traitement de tumeurs cérébrales |
| TWI404538B (zh) * | 2007-02-02 | 2013-08-11 | Panaphix Inc | 砷化合物用於治療疼痛及發炎之用途 |
| WO2019178643A1 (fr) * | 2018-03-22 | 2019-09-26 | Komipharm International Australia Pty Ltd | Composition pharmaceutique comprenant du méta-arsénite et procédé de fabrication |
| WO2021159187A1 (fr) * | 2020-02-16 | 2021-08-19 | Komipharm International Australia Pty Ltd | Méthode de traitement à l'aide de méta-arsénite |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020083458A (ko) * | 2001-04-28 | 2002-11-02 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 메타아르세나이트 염 또는 이의혼합물을 함유한 항암제 조성물 |
-
2005
- 2005-03-31 WO PCT/KR2005/000938 patent/WO2006104292A1/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020083458A (ko) * | 2001-04-28 | 2002-11-02 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 메타아르세나이트 염 또는 이의혼합물을 함유한 항암제 조성물 |
| KR20020083678A (ko) * | 2001-04-28 | 2002-11-04 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물 |
Non-Patent Citations (1)
| Title |
|---|
| WANG Z.Y.: "Arsenic compounds as anticancer agents", CANCER CHEMOTHER. PHARMACOL., vol. 48, no. SUPPL. 1, August 2001 (2001-08-01), pages S72 - S76 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2665362C2 (ru) * | 2007-02-02 | 2018-08-29 | Панафикс Инк. | Применение соединений мышьяка для лечения отторжения ткани или органа |
| TWI404538B (zh) * | 2007-02-02 | 2013-08-11 | Panaphix Inc | 砷化合物用於治療疼痛及發炎之用途 |
| US10058570B2 (en) | 2007-02-02 | 2018-08-28 | Panaphix Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| WO2009072779A1 (fr) * | 2007-12-04 | 2009-06-11 | Sang Bong Lee | Composition contenant du méta-arsénite de sodium pour le traitement de l'hépatite c |
| RU2568834C2 (ru) * | 2009-09-10 | 2015-11-20 | Коминокс, Инк. | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами |
| WO2011031890A3 (fr) * | 2009-09-10 | 2011-08-25 | Kominox, Inc. | Thérapie ciblée sur des cellules souches cancéreuses et contre un cancer pharmacorésistant |
| WO2011034775A3 (fr) * | 2009-09-18 | 2011-10-06 | Kominox, Inc. | Méthodes de traitement de tumeurs cérébrales |
| WO2019178643A1 (fr) * | 2018-03-22 | 2019-09-26 | Komipharm International Australia Pty Ltd | Composition pharmaceutique comprenant du méta-arsénite et procédé de fabrication |
| JP2021518434A (ja) * | 2018-03-22 | 2021-08-02 | コミファーム インターナショナル オーストラリア ピーティーワイ リミテッド | メタ亜ヒ酸塩を含む医薬組成物および製造方法 |
| JP7419333B2 (ja) | 2018-03-22 | 2024-01-22 | コミファーム インターナショナル オーストラリア ピーティーワイ リミテッド | メタ亜ヒ酸塩を含む医薬組成物および製造方法 |
| IL277456B1 (en) * | 2018-03-22 | 2024-07-01 | Komipharm Int Australia Pty Ltd | Medicinal composition containing meta arsenite and production method |
| IL277456B2 (en) * | 2018-03-22 | 2024-11-01 | Komipharm Int Australia Pty Ltd | Pharmaceutical composition comprising meta arsenite and method of manufacture |
| US12257347B2 (en) | 2018-03-22 | 2025-03-25 | Komipharm International Australia Pty Ltd | Pharmaceutical composition comprising meta arsenite and method of manufacture |
| CN115243692A (zh) * | 2020-02-16 | 2022-10-25 | 科微范国际澳大利亚私人有限公司 | 使用偏亚砷酸盐的治疗方法 |
| WO2021159187A1 (fr) * | 2020-02-16 | 2021-08-19 | Komipharm International Australia Pty Ltd | Méthode de traitement à l'aide de méta-arsénite |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0180019B1 (ko) | 개량된 화학적 화합물 | |
| US20070253980A1 (en) | New pharmaceutical composition from natural materials for regulating immunity, its preparation method and use | |
| JPH0232093A (ja) | 抗レトロウィルスジフルオロ化ヌクレオシド類 | |
| CN111265527A (zh) | 萘酚喹及其药学上可接受的盐在制备抗冠状病毒药物中的用途 | |
| WO2006104292A1 (fr) | Composition pharmaceutique qui comprend de l’acide arsénique, du meta-arsénite et des sels pharmaceutiquement acceptables | |
| AU775459B2 (en) | Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, DNA viruses and retroviruses | |
| CN1935762A (zh) | 一类对映桉烷醇类倍半萜抑制乙肝病毒的医药用途 | |
| EP2241571B1 (fr) | Procédé de préparation de la 6-méthoxy-2',3'-dideoxyguanosine | |
| KR20000069296A (ko) | 항바이러스 활성을 갖는 살비아 종의 추출물 | |
| JP2013517262A (ja) | 抗エイズ剤としての多環式化合物の医薬的使用 | |
| KR100532542B1 (ko) | 아르세닉산, 메타아르세나이트 또는 이들의 약제학적허용가능한 염을 함유한 에이즈 예방 및 치료용 약제 조성물 | |
| TWI754260B (zh) | 魚針草內酯抗新型冠狀病毒之用途 | |
| EP0476391B1 (fr) | Composition anti-SIDA contenant cépharanthine comme agent thérapeutique | |
| RU2531945C2 (ru) | Средство против передачи вич/спид половым путем | |
| AU760967B2 (en) | Herbal composition for the prophylaxis and treatment of AIDS | |
| RU2182828C1 (ru) | Композиция, обладающая антивич и антигерпесной активностью | |
| EP0290817A2 (fr) | Utilisation d'oxétanocine pour inhiber HIV | |
| CN107320471A (zh) | 一种治疗结核病的环丝氨酸药物组合物及其应用 | |
| EP0765662B1 (fr) | Utilisation de l'acide 5,6-o-benzylidene-l-ascorbique ou ses sels pour la fabrication d'un medicament pour le traitement du vih | |
| WO2018107614A1 (fr) | Utilisation de la lutéoline dans la préparation d'un médicament pour la prévention et le traitement d'une infection par le virus de la dengue | |
| KR20220139708A (ko) | 마이토피큐를 유효성분으로 포함하는 결핵의 예방 또는 치료용 약학 조성물 | |
| WO2001081339A1 (fr) | Composes pour le traitement ou la prevention du paludisme et procedes pour le traitement du paludisme | |
| CN117679412A (zh) | 异补骨脂查尔酮和氟康唑联合用药在制备抗真菌药物中的应用 | |
| EP1143981A1 (fr) | Traitement et prevention d'infections par le vih et d'autres infections virales | |
| CN100464748C (zh) | 消旋去甲胡桐素a制备抗爱滋病毒类药物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05805011 Country of ref document: EP Kind code of ref document: A1 |